首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL12A |
| Uniprot No | P29459 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-219aa |
| 氨基酸序列 | RNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHE DITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMAL CLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNF NSETVPQKSSLEEPDFYKTKIKLCILLHAFRIRAVTIDRVMSYLNAS |
| 预测分子量 | 49 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL12A重组蛋白的3篇参考文献及其摘要概括：
---
1. **"Cloning and expression of murine IL-12"**
*Wolf, S.F., et al. (1991)*
摘要：研究报道了IL12A和IL12B亚基的基因克隆，通过共表达生成功能性重组IL-12蛋白，验证其促进T细胞和NK细胞分泌IFN-γ的能力。
2. **"Production and characterization of recombinant human interleukin-12"**
*Gubler, U., et al. (1991)*
摘要：描述从人淋巴细胞cDNA文库中分离IL12A和IL12B基因，重组蛋白在哺乳细胞中表达，证实其诱导IFN-γ并增强自然杀伤(NK)细胞活性。
3. **"Antitumor activity of interleukin-12 in murine models"**
*Brunda, M.J., et al. (1993)*
摘要：通过重组IL-12蛋白实验，证明其在多种小鼠肿瘤模型中显著抑制肿瘤生长，并增强CD8+ T细胞介导的细胞毒性反应。
---
以上文献涵盖IL12A重组蛋白的基因克隆、表达及功能验证，适用于免疫学和肿瘤治疗研究。如需更多细节，建议通过PubMed或学术数据库查询具体全文。
**Background of IL12A Recombinant Protein**
Interleukin-12A (IL12A), also known as IL-12p35. is a key subunit of the heterodimeric cytokine IL-12. which plays a pivotal role in bridging innate and adaptive immunity. IL-12 is composed of two covalently linked subunits, IL12A (p35) and IL12B (p40), forming the bioactive IL-12p70 protein. This cytokine is primarily produced by antigen-presenting cells, such as dendritic cells and macrophages, in response to microbial or inflammatory stimuli.
IL-12 signaling through the IL-12 receptor (IL-12R) on T cells and natural killer (NK) cells drives the differentiation of naïve T cells into T-helper type 1 (Th1) cells, promoting interferon-gamma (IFN-γ) production and enhancing cytotoxic activity. These functions make IL-12 critical in combating intracellular pathogens and tumors. However, its systemic administration in therapeutics has been limited due to toxicity, spurring interest in targeted delivery or engineered variants.
Recombinant IL12A protein is produced using biotechnological platforms, such as mammalian expression systems (e.g., CHO cells) or prokaryotic systems (e.g., *E. coli*), ensuring high purity and bioactivity. It is widely utilized in research to study IL-12/IL-12R signaling mechanisms, immune cell modulation, and its therapeutic potential in cancer immunotherapy, infectious diseases, and vaccine adjuvants.
Recent advances include the development of IL-12-based fusion proteins or gene therapies to improve pharmacokinetics and reduce off-target effects. Despite challenges, IL12A remains a cornerstone in immunology research and a promising candidate for next-generation immunotherapies.
×
